Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 11/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153110 | 0.84 | PTGS2 (0.40) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6153167 | 0.83 | PTGS2 (0.39) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6153836 | 0.82 | CYP4F2 (0.51) | CYP4F2CYP4A11PTGS2PTGS1ALOX5 | |
| SCHEMBL6153873 | 0.80 | PTGS2 (0.40) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6154300 | 0.74 | CNKSR1 (0.38) | PTGS2PTGS1ALOX5ALDH1A1CYP3A4 | |
| SCHEMBL23256386 | 0.71 | CYP4F2 (0.47) | CYP4F2CYP4A11ALDH1A1GAAGPR35 | |
| SCHEMBL25629660 | 0.71 | CYP4F2 (0.56) | CYP4F2CYP4A11ALDH1A1GAACYP1A2 | |
| SCHEMBL8741606 | 0.70 | RXRA (0.48) | CYP4F2CYP4A11ALDH1A1GAA | |
| SCHEMBL6154436 | 0.69 | PTGS2 (0.37) | PTGS2PTGS1ALOX5 | |
| SCHEMBL31110728 | 0.69 | CYP4F2 (0.43) | CYP4F2CYP4A11ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499604-A1 | DIHYDROBENZOFURAN AND DIHYDROBENZOTHIOPHENE 2,4-PENTAIDENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | Allergan, Inc. (US) | 2005-01-26 | — | — | EP | disclosed |
| US-6720423-B2 | SKIN RELATED DISEASES; PROMOTE THE EXPRESSION OF OR BIND TO RECEPTORS BELONGING TO THE STEROID OR THYROID RECEPTOR SUPERFAMILY. | ALLERGAN, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20030216570-A1 | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | ALLERGAN, INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003093257-A1 | DIHYDROBENZOFURAN AND DIHYDROBENZOTHIOPHENE 2,4-PENTAIDENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216570-A1 | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | RXRB, RXRA, RXRG | CYP4F2 53/4885CYP4A11 304/4885PTGS2 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.